{
    "clinical_study": {
        "@rank": "137934", 
        "acronym": "PROactive", 
        "arm_group": [
            {
                "arm_group_label": "Telecoaching", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive daily coaching by an automated telehealth system and coaching by the investigator during study visits, in addition to the usual care."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Other", 
                "description": "Participants will receive the usual care but will NOT receive daily coaching by telehealth system."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will test two instruments to measure physical activity in COPD patients: A\n      questionnaire and two small physical activity monitors .Patients will be randomized to\n      either receive the telecoaching program in addition to usual care or only the usual care.\n      Study will include around 510 patients in 5 countries in Europe."
        }, 
        "brief_title": "Study to Evaluate the Impact of the \"PROactive Telecoaching Program\" on Physical Activity in Patients With COPD.", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "detailed_description": {
            "textblock": "Chronic Obstructive Pulmonary Disease (COPD) has a negative influence on physical activity\n      hence it may be beneficial for patients to increase physical activity levels. This study\n      will test two instruments to measure physical activity: A questionnaire (completed on a\n      personal digital assistant) and a physical activity monitor which patient wear during the\n      day. Patients will be randomized to either receive the Telecoaching program in addition to\n      usual care or only the usual care. The study will involve 4 clinic visits as well as some\n      phone calls over duration of 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Male and female patients \u2265 40 years of age\n\n          -  Diagnosis of COPD (GOLD criterion: post bronchodilator FEV1/FVC< 70%)\n\n          -  Current or ex-smokers with a smoking history equivalent to at least 10 pack years (1\n             pack year = 20 cigarettes smoked per day for 1 year)\n\n          -  Patients should have at least 4 days of physical activity data recorded via activity\n             monitor during 7 days prior to visit 101.\n\n        Exclusion Criteria:\n\n        Patients fulfilling any of the following criteria are not eligible for inclusion in this\n        study.\n\n          -  Orthopedic, neurological or other complaints that significantly impair normal\n             biomechanical movement patterns, as judged by the investigator. Specifically if the\n             patients' condition/ co-morbidities are such that physical activity cannot be\n             increased.\n\n          -  Respiratory diseases other than COPD (e.g. asthma)\n\n          -  Cognitive reading impairment and/or difficulties to manage electronic devices\n             precluding interaction with the health base and PDA, as judged by the investigator\n\n          -  Participating in or scheduled to start a rehabilitation program during the study. If\n             the patient wishes to participate in pulmonary rehabilitation for any reason the\n             patient can be enrolled in the study only at the end of rehabilitation.\n\n          -  Women of child-bearing potential who have the intention to become pregnant during the\n             course of the study and pregnant or nursing (lactating) women, where pregnancy is\n             defined as the state of a female after conception and until the termination of\n             gestation, confirmed by a positive \u03b2-hCG laboratory test."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992081", 
            "org_study_id": "CIDD001D2101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Telecoaching", 
                "description": "The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug\u00ae), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.", 
                "intervention_name": "Automated telehealth system", 
                "intervention_type": "Device", 
                "other_name": "telehealth system"
            }, 
            {
                "arm_group_label": [
                    "Telecoaching", 
                    "Control"
                ], 
                "description": "Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)", 
                "intervention_name": "Usual care", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "COPD, Physical Activity, Telecoaching, PROactive", 
        "lastchanged_date": "May 14, 2014", 
        "location_countries": {
            "country": [
                "Belgium", 
                "Greece", 
                "Netherlands", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A 6-month Multicenter Randomized Trial to Evaluate the Impact of the \"PROactive Telecoaching Program\" on Physical Activity in Patients With COPD", 
        "overall_official": [
            {
                "affiliation": "Novartis Pharmaceuticals", 
                "last_name": "Novartis Pharmaceuticals", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "PROactive is part of the European Innovative Medicines Initiative (IMI)", 
                "last_name": "Innovative Medicines Initiative", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Switzerland: Federal Office of Public Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Impact of telecoaching program on the physical activity of COPD patients will be measured via the use of two PROactive monitors (ActiGraph\u00ae and DynaPort\u00ae) and a PDA to complete the PROactive questionnaire.", 
                "measure": "The impact of telecoaching program on the physical activity", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Construct validity of the PROactive instrument will be measured via the use of two PROactive monitors (ActiGraph\u00ae and DynaPort\u00ae) and a PDA to complete the PROactive questionnaire.", 
                "measure": "The construct validity of the PROactive instrument.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Responsiveness of the PROactive instrument will be measured via the use of two PROactive monitors (ActiGraph\u00ae and DynaPort\u00ae) and a PDA to complete the PROactive questionnaire.", 
                "measure": "The responsiveness of the PROactive instrument.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992081"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "collaborator": {
                "agency": "Innovative Medicines Initiative", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}